Natera Remains Druckenmiller’s Top Holding, but Risks Are Rising
Natera’s oncology testing engine is accelerating, yet losses, dilution and a demanding valuation complicate the case for copying Druckenmiller.
Makkler Newsroom · Sep 16, 05:18 AM · 2 min read